Plasse T, Ohnuma T, Bruckner H, Chamberlain K, Mass T, Holland J F
Cancer. 1982 Jul 1;50(1):27-31. doi: 10.1002/1097-0142(19820701)50:1<27::aid-cncr2820500107>3.0.co;2-f.
Fifty-seven adult patients receiving chemotherapy were treated with a total of 133 infusions using portable user-worn infusion pumps, the Autosyringe AS2F Cormed ML6-4, and two earlier versions of the latter, the Sigmamotor ML6-2 and ML6-3. Ninety-eight infusions were given on an ambulatory basis. Fourteen infusions were given through peripheral venous catheters, 115 through central venous catheters, and four intra-arterially. Of 127 evaluable infusions, 65 were completed within 5% and 87 within 10% of the planned rate; results are similar for both inpatient and outpatient infusions. The Cormed ML6-4 pump was equal to the Autosyringe AS2F in reliability but superior to the latter in patient preference. There were no instances of dangerously rapid administration of the drug. The only serious catheter complications were a pneumothorax after insertion of a subclavian catheter in one patient and cellulitis in a leukopenic patient with a Broviac catheter. All but three patients preferred outpatient therapy to hospitalization. Outpatient therapy costs about $300 per day less than in-hospital treatment.
57名接受化疗的成年患者使用便携式可穿戴输液泵Autosyringe AS2F Cormed ML6 - 4及其两个早期版本Sigmamotor ML6 - 2和ML6 - 3共进行了133次输液治疗。其中98次输液是在门诊进行的。14次输液通过外周静脉导管给药,115次通过中心静脉导管给药,4次通过动脉内给药。在127次可评估的输液中,65次在计划速率的5%以内完成,87次在10%以内完成;住院和门诊输液的结果相似。Cormed ML6 - 4泵在可靠性方面与Autosyringe AS2F相当,但在患者偏好方面优于后者。没有出现药物危险快速给药的情况。唯一严重的导管并发症是1例患者锁骨下导管插入后发生气胸,1例白细胞减少患者使用Broviac导管发生蜂窝织炎。除3名患者外,所有患者都更喜欢门诊治疗而非住院治疗。门诊治疗每天的费用比住院治疗少约300美元。